Celltrion launches three new biosimilars in Brazil
Celltrion Inc. has launched three additional biosimilars in Brazil, expanding its local product portfolio to 10, the company said Thursday.
The new products are Qoyvolma, a treatment for autoimmune diseases containing ustekinumab and marketed as Steqeyma in other markets, and Stoboclo and Osenvelt, denosumab-based treatments for bone diseases.
Celltrion plans to offer the products in various dosages and formulations to better meet the needs of local healthcare providers and patients, while expanding prescriptions and sales.
Its Brazilian subsidiary will leverage its sales infrastructure and local network to establish the new products in the market. The company also expects its reliable supply capabilities, competitive pricing, and product quality to support its expansion in Brazil.
Celltrion plans to launch two more products by year-end: Eydenzelt, an aflibercept treatment for eye diseases, and Aptozma, a tocilizumab treatment for autoimmune diseases.
“We will continue to expand our product portfolio and therapeutic areas, accelerating growth in Brazil and other Latin American markets,” said a company official.